Prescrire Int. 2009 Dec;18(104):276-9.
(1) Gene therapy consists of inserting foreign genetic material into a patient's cells to correct a health disorder; (2) Only a fraction of gene therapy trials involve hereditary single-gene disorders. Most trials focus on acquired disorders such as cancer and cardiovascular disease; (3) The therapeutic gene can be delivered directly into the target organ or the general circulation, or alternatively into cells that are first isolated from the patient and then reinjected; (4) One of the main problems with gene therapy is finding an appropriate vector (viral or non-viral) that is both effective and safe. Most currently available vectors confer only weak and transient therapeutic gene expression. In addition, many carry major risks such as immunological disorders and oncogenicity; (5) In early 2009, only one therapeutic gene product is commercially available, in China.
(1) 基因治疗是指将外源遗传物质导入患者细胞以纠正健康紊乱;(2) 只有一小部分基因治疗试验涉及遗传性单基因疾病。大多数试验集中于诸如癌症和心血管疾病等后天性疾病;(3) 治疗性基因可直接导入靶器官或全身循环,或者导入先从患者体内分离然后再重新注入的细胞;(4) 基因治疗的主要问题之一是找到一种既有效又安全的合适载体(病毒或非病毒)。目前大多数可用载体仅能产生微弱且短暂的治疗性基因表达。此外,许多载体还带有诸如免疫紊乱和致癌性等重大风险;(5) 2009年初,只有一种治疗性基因产品在中国上市。